A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% ...

A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% ...

A Phase IIb/III trial with infants entering their first respiratory syncytial virus (RSV) season met its primary endpoints.

Today, The Lancet published the first real-world data analysis of respiratory syncytial virus (RSV) vaccine efficacy among ...

There were no safety concerns identified among older adults following revaccination with the investigational respiratory syncytial virus vaccine mRNA-1345, and immune responses elicited by ...

A large new study says the RSV vaccine is 80% effective at preventing hospitalization in older adults due to complications from the illness, and works just as well at protecting them from death or ...

Connecticut officials said Friday that the state has had two deaths from the flu and 15 to 20 people still die of COVID-19 ...

The RSV vaccine Abrysvo was highly effective against hospital and ED encounters in a large cohort of older adults with comorbidities and immunocompromising conditions.

A multi-state study, published in The Lancet, is one of the first real world data analyses of the effectiveness of the ...

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

A multi-state study, published in The Lancet, is one of the first real world data analyses of the effectiveness of the RSV -- short for respiratory ...

The respiratory syncytial virus (RSV) vaccines were about 80% effective in older adults during the 2023-24 respiratory disease season, which was the first season after the shot was approved in the US, ...